ROIV
Roivant Sciences Ltd.
Next earnings ≈ Aug 19, 2026 · est. from filing cadence
Last earnings +14.9% on 2026-05-20
$34.07
▲ +0.15%$34.07▲ +196.26%
over 1Y
L $10.74EODHDH $34.07
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.1%
1W+9.0%
1M+15.2%
3M+28.5%
YTD+55.4%
1Y+196.3%
Hold
Conviction
Horizon
Long (>12mo)
Street · 19 analysts
Strong Buy
Cash-rich clinical-stage biopharma with no product revenue — a binary pipeline bet, not a fundamentals story.
Revenue $8.26M · FY2026
Roivant is a clinical-stage biopharmaceutical holding company with effectively no commercial product revenue: FY2026 revenue was just $8.26M (down 71.6% YoY) against R&D expense of $682M and an operating loss of $515M. The MD&A is explicit that the company does not expect product revenues until it receives regulatory approval for a candidate, so every conventional valuation lens — a -58.2 P/E and an absurd P/S near 2737 — is meaningless here. This is not a company you value on earnings; it is a portfolio of pipeline options (brepocitinib under FDA review for dermatomyositis, IMVT-1402 via majority-held Immunovant, and mosliciguat) wrapped around a balance sheet.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | $55.3M | $31.5M | $32.7M | $29.1M | $8.26M |
| Gross profit | — | — | — | — | — |
| Operating income | -$1.35B | -$907M | $4.50B | -$1.00B | -$515M |
| Net income | -$845M | -$1.01B | $4.35B | -$172M | -$300M |
| Diluted EPS | -$1.26 | -$1.42 | $5.23 | -$0.24 | -$0.54 |
| Net margin | -1528.9% | -3200.2% | 13294.2% | -592.0% | -3629.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$23.5B
EV / EBITDA—
EV / Sales2848.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-1.2%
FCF yield-3.1%
Quality & risk
ROIC (est.)-8.2%
Free cash flow-$759M
Total debt$443M
Net cash$977M
Altman Z-Score35.93 safe
Piotroski F-Score0/8
Capital returns
Buyback yield5.3%
Dividend yield (est.)—
Shareholder yield5.3%
Shares Δ YoY+5.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-242026-06-26open ↗144Filing2026-06-26open ↗144Filing2026-06-25open ↗144Filing2026-06-24open ↗4Period ending 2026-06-202026-06-23open ↗4Period ending 2026-06-202026-06-23open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗144Filing2026-05-22open ↗S-8Filing2026-05-20open ↗10-KPeriod ending 2026-03-312026-05-20open ↗8-KPeriod ending 2026-05-202026-05-20open ↗
Frequently asked
- Is Roivant Sciences Ltd. (ROIV) a buy?
- ROIV currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Cash-rich clinical-stage biopharma with no product revenue — a binary pipeline bet, not a fundamentals story.
- What is Roivant Sciences Ltd.'s quality score?
- ROIV scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001635088, latest 10-K filed 2026-05-20) · EODHD · analysis by claude-code · as of 6/21/2026, 8:41:00 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.